Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Lowers Price Target to $247

Benzinga · 1d ago
Morgan Stanley analyst Sean Laaman maintains Axsome Therapeutics (NASDAQ:AXSM) with a Equal-Weight and lowers the price target from $251 to $247.